Business Wire

SKY-LABS

22.2.2021 15:02:11 CET | Business Wire | Press release

Share
Sky Labs CART-I Invited to a Clinical Study of Oxford University Professor Betts

Sky Labs , a healthcare start-up, announced that CART-I, its ring-type heart-monitoring device, had been provided for Timothy Betts, professor of medicine at Oxford University, for his clinical research.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005010/en/

Professor Timothy Betts is a cardiologist and arrhythmia specialist. He is a key figure for clinical research in cardiac rhythm management and associate professor of cardiovascular medicine at Oxford University. He is also a member of the Oxford Biomedical Research Center and the UK representative on the EHRA National Cardiac Societies Committee.

Atrial fibrillation patients are advised to take anticoagulants to prevent the risk of stroke. However, it is not easy to identify the symptoms. Professor Betts plans to conduct a clinical study with Sky Labs CART-I, Medtronic Reveal LINQ II and Apple Watch to detect atrial fibrillation symptoms and alert the patients to take anticoagulants when needed.

Fifty patients recruited for the study will be inserted with a Reveal LINQ II implantable cardiac monitor (ICM). Then they will receive a Sky Labs CART-I ring or an Apple Watch. The ability of the ring and the watch to monitor heart rhythm and alert atrial fibrillation episodes will be analyzed in comparison with the ICM.

CART-I is the world’s first ring-type heart-monitoring device. The photoplethysmography (PPG) sensor in the ring monitors the bloodstream in the finger and continuously measures the irregular pulse waves of atrial fibrillation. Electrocardiogram (ECG) can be also measured by simply placing the fingers on the metal part of the ring.

Professor Timothy Betts said, “I’m pleased to conduct a study to monitor the atrial fibrillation of patients by using CART-I and utilize the data to guide atrial fibrillation treatment. CART-I featuring innovative design and multiple functions will be of great help to patients and medical staffs.”

Jack Lee, CEO of Sky Labs, said, “The study will be an opportunity for us to enter the global healthcare market. CART-I will make a good combination with the ICM in monitoring heart rhythm and providing meaningful data for patients and doctors.”

Sky Labs’ CART-I won the Digital Health & Technology Competition of the European Society of Cardiology for 2 consecutive years from 2018. The company was selected as the ‘technology pioneer’ of the World Economic Forum 2019 and invited to the annual forum.

About Sky Labs

Sky Labs developed CART (Cardio Tracker) – I, a ring-type medical device to monitor heart signals and detect diseases by using optical sensors. It monitors atrial fibrillation, which cannot be detected in advance, 24/7. The results can be checked in real time on the CART-app of your smartphone. Very light and water-resistant, the CART ring is easy to use and causes no inconvenience to your daily life. Winning the final of the Grants4Apps held by Bayer, a German multinational pharmaceutical company, in 2017, Sky Labs attracted investment from Bayer Headquarters. Sky Labs and the Charité in Germany, one of Europe’s largest hospitals, have been considering collaborative clinical research in heart-related diseases since May 2018. It is the only Korean company which won the Digital Health and Technology Competition of the European Society of Cardiology for 2 consecutive years. In addition, the company was invited as a technology pioneer to the World Economic Forum 2019.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

INNIO Group Announces Filing of Registration Statement for Proposed Initial Public Offering11.5.2026 21:49:00 CEST | Press release

INNIO Group ("INNIO"), a leading global distributed energy solutions provider, today announces that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its common shares. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511389675/en/ INNIO Group Announces Filing of Registration Statement for Proposed Initial Public Offering The timing of the offering, number of shares to be offered and the price range for the proposed offering have not yet been determined. INNIO has applied to list its common shares on the Nasdaq Global Select Market under the ticker symbol "INIO." Goldman Sachs & Co. LLC, J.P. Morgan and Morgan Stanley are acting as joint lead book-running managers for the proposed offering. BofA Securities, Barclays and Citigroup are acting as book-running managers for the proposed offering. Baird, BNP Paribas

Only 7% of Companies Achieve Full Compliance as Global Expansion Increases Legal Complexity11.5.2026 15:00:00 CEST | Press release

47% of general counsels say beneficial ownership rules pose the biggest risks to legal operations44% lack confidence in meeting cross-border data security requirements As businesses accelerate their global expansion in 2026, compliance fails to keep pace. In fact, only 7% of organizations report full compliance across their global entities, according to a new study by CSC, the leading provider of global business administration and compliance solutions. CSC surveyed 350 general counsel (GCs) and senior legal professionals across Europe, North America, and Asia Pacific to examine how their teams navigate international expansion, regulatory pressure, and the increasing adoption of artificial intelligence (AI).¹ The findings appear in CSC’s latest report, General Counsel Barometer 2026: From Complexity to Control. Most organizations report partial compliance, with over half (53%) estimating they are 50–75% compliant, and a further 35% placing themselves between 76%–99%. This leaves just 7%

IFF Opens Vanilla Innovation Center in Madagascar11.5.2026 14:15:00 CEST | Press release

Advancing science‑led flavor innovation where vanilla is grown IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health & bioscience—today announced the opening of its Vanilla Innovation Center in Madagascar, reinforcing vanilla as a strategic and priority tonality for IFF and strengthening its ability to innovate at origin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260508110162/en/ IFF's Vanilla Innovation Center in Madagascar “The opening of the center marks an important step in how we approach vanilla innovation,” said Adam Jańczuk, Ph.D., senior vice president, research, creation and design, Taste, IFF. “By strengthening our presence at origin, we connect science, creativity and sustainability more closely, responding to climate changes, safeguarding quality and creating value across the supply chain.” Located in Toamasina, Madagascar’s principal seaport, near vanilla growing areas and post‑h

ARIS Recognised as a Leader in Gartner® Magic Quadrant™ for Process Intelligence Platforms, Believes This Reinforces Its Role in Enabling Enterprise AI at Scale11.5.2026 14:00:00 CEST | Press release

ARIS, the process context foundation platform for enterprise AI deployment, today announced its recognition as a Leader in the Gartner® Magic Quadrant™ for Process Intelligence Platforms. This is the fourth consecutive year that ARIS has been recognized as a Leader in the report and the company believes it underscores a continued commitment to innovation and growth as enterprises focus on turning AI ambition into measurable business outcomes. While technology has advanced rapidly, companies are struggling to operationalise AI across complex operating models. ARIS sees this recognition by Gartner as a reflection of its strength in delivering a single unified platform for process intelligence, providing the context layer on which G2000 organisations can successfully deploy and scale agentic AI. “AI is moving from experimentation to execution – but many enterprises are finding it difficult to scale,” said Guillaume Bacuvier, CEO of ARIS. “The reason is simple: AI lacks the context it need

HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors11.5.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has submitted a De Novo request to the U.S. Food and Drug Administration seeking authorization to expand the use of its Edison® Histotripsy System to include the destruction of kidney (renal) tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511268688/en/ HistoSonics Edison® Histotripsy System This milestone marks a significant step forward in the company’s mission to transform the treatment of solid tumors with a completely non-invasive technology that harnesses focused ultrasound to mechanically liquefy and destroy targeted tissue, reducing the risk of many complications and side effects associated with surgery, radiation, and other common therapies. “This submission is an important milestone in expanding histotripsy beyond the liver and into the kidney, an area where patients and physicians are s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye